José António Pereira da Silva

José António Pereira da Silva

Auto-generated profile, based on publicly available information

José António Pereira da Silva

Rheumatology Department, Coimbra Hospital and University Centre, Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JSJosef S Smolen
Josef S Smolen
RLRobert B M Landewé
Robert B M Landewé
JBJohannes W J Bijlsma
Johannes W J Bijlsma
GBGerd R Burmester
Gerd R Burmester
MDMaxime Dougados
Maxime Dougados
DHDésirée van der Heijde
Désirée van der Heijde

1 June 2017 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JSJosef S Smolen
Josef S Smolen
RLRobert Landewé
Robert Landewé
JBJohannes Bijlsma
Johannes Bijlsma
GBGerd Burmester
Gerd Burmester
KCKaterina Chatzidionysiou
Katerina Chatzidionysiou
DHDésirée van der Heijde
Désirée van der Heijde

1 July 2013 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
LFLinda Fernandes
Linda Fernandes
KHKåre B Hagen
Kåre B Hagen
JBJohannes W J Bijlsma
Johannes W J Bijlsma
OAOyvor Andreassen
Oyvor Andreassen
PCPia Christensen
Pia Christensen
TVThea Vlieland
Thea Vlieland

1 May 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
CSCarina Götestam Skorpen
Carina Götestam Skorpen
MHMaria Hoeltzenbein
Maria Hoeltzenbein
ATAngela Tincani
Angela Tincani
RFRebecca Fischer-Betz
Rebecca Fischer-Betz
EEElisabeth Elefant
Elisabeth Elefant
MØMonika Østensen
Monika Østensen
A European League Against Rheumatism (EULAR) task force was established to define points to consider on use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Based on a systematic literature review and pregnancy exposure data from several registries, statements on the compatibility of antirheumatic drugs during pregnancy and lactation were developed. The level of agreement among experts in regard to statements and propositions of use in clinical practice was established by Delphi voting. The task force defined 4 overarching principles and 11 points to consider for use of antirheumatic drugs during pregnancy and lactation. Compatibility with pregnancy and lactation was found for antimalarials, sulfasalazine, azathioprine, ciclosporin, tacrolimus, colchicine, intravenous immunoglobulin and glucocorticoids. Methotrexate, mycophenolate mofetil and cyclophosphamide require discontinuation before conception due to proven teratogenicity. Insufficient documentation in regard to fetal safety implies the discontinuation of leflunomide, tofacitinib as well as abatacept, rituximab, belimumab, tocilizumab, ustekinumab and anakinra before a planned pregnancy. Among biologics tumour necrosis factor inhibitors are best studied and appear reasonably safe with first and second trimester use. Restrictions in use apply for the few proven teratogenic drugs and the large proportion of medications for which insufficient safety data for the fetus/child are available. Effective drug treatment of active inflammatory rheumatic disease is possible with reasonable safety for the fetus/child during pregnancy and lactation. The dissemination of the data to health professionals and patients as well as their implementation into clinical practice may help to improve the management of pregnant and lactating patients with rheumatic disease.

1 April 2008 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
SCS F Carville
S F Carville
LALars Arendt-Nielsen
Lars Arendt-Nielsen
HBH Bliddal
H Bliddal
FBF Blotman
F Blotman
Jaime BrancoJaime Branco
Jaime Branco
ECE H Choy
E H Choy
Objective: To develop evidence-based recommendations for the management of fibromyalgia syndrome. Methods: A multidisciplinary task force was formed representing 11 European countries. The design of the study, including search strategy, participants, interventions, outcome measures, data collection and analytical method, was defined at the outset. A systematic review was undertaken with the keywords “fibromyalgia”, “treatment or management” and “trial”. Studies were excluded if they did not utilise the American College of Rheumatology classification criteria, were not clinical trials, or included patients with chronic fatigue syndrome or myalgic encephalomyelitis. Primary outcome measures were change in pain assessed by visual analogue scale and fibromyalgia impact questionnaire. The quality of the studies was categorised based on randomisation, blinding and allocation concealment. Only the highest quality studies were used to base recommendations on. When there was insufficient evidence from the literature, a Delphi process was used to provide basis for recommendation. Results: 146 studies were eligible for the review. 39 pharmacological intervention studies and 59 non-pharmacological were included in the final recommendation summary tables once those of a lower quality or with insufficient data were separated. The categories of treatment identified were antidepressants, analgesics, and “other pharmacological” and exercise, cognitive behavioural therapy, education, dietary interventions and “other non-pharmacological”. In many studies sample size was small and the quality of the study was insufficient for strong recommendations to be made. Conclusions: Nine recommendations for the management of fibromyalgia syndrome were developed using a systematic review and expert consensus.

1 August 2002 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
FBF Buttgereit
F Buttgereit
JSJ A P Da Silva
J A P Da Silva
MBM Boers
M Boers
GBG-R Burmester
G-R Burmester
MCM Cutolo
M Cutolo
JBJ W J Bijlsma
J W J Bijlsma
In rheumatology and other medical specialties there is a discrepancy between the widespread use and the imprecise designation of glucocorticoid treatment regimens. Verbal descriptions of glucocorticoid treatment regimens used in various phases of diseases vary between countries and institutions. Given this background, a workshop under the auspices of the EULAR Standing Committee on International Clinical Studies including Therapeutic Trials was held to discuss this issue and to seek a consensus on nomenclature for glucocorticoid treatment. This report summarises the panel's discussion and recognises that answers derived from consensus conferences are not definitive. Nevertheless, recommendations on glucocorticoid treatment are presented that (1) reflect current and best knowledge available and (2) take into account current clinical practice. A question-answer rationale presentation style has been chosen to convey the messages, to summarise the meeting in a readable format, and to avoid dogmatism.